{"schema_version":"secwatch.filing_event.v1","accession":"0001683168-22-008034","form_type":"8-K","ticker":"ODYY","cik":"0001626644","company_name":"Odyssey Health, Inc.","filed_at":"2022-11-25T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.485509+00:00","generated_at":"2026-06-21T13:04:12.863443+00:00","sec_items":["8.01","7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Odyssey Health provides update on concussion drug program; Phase I trial completed, safety shown","bullets":["Completed FDA-required Phase I human clinical trial; drug safe, well tolerated, no accumulation over 10 days.","Raised over $5M in funding; access to Lincoln Park equity line of up to $10M.","Added two key executives with pharmaceutical drug development experience to management.","Filed patent application for novel breath-propelled intranasal delivery device.","Developed nanoparticle spray-dried formulation in partnership with UK partner under GMP."],"urls":{"canonical":"https://secwatch.observer/filing/0001683168-22-008034","json":"https://secwatch.observer/filing/0001683168-22-008034.json","markdown":"https://secwatch.observer/filing/0001683168-22-008034.md","text":"https://secwatch.observer/filing/0001683168-22-008034.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1626644/000168316822008034/0001683168-22-008034-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1626644/000168316822008034/odyssey_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T13:04:12.863443+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}